ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Otsuka and Jiangsu HengRui Medicine side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

OtsukaJiangsu HengRui Medicine
studies on the registry7841,066
open to participants now55307
phase 3 studies under way31105
reach primary completion within a year23130
programswith a study of their own in two years25155+1 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOtsukaJiangsu HengRui Medicine
Phase 1

Otsuka: 12 of its 25 programs at phase 1

  1. VIS171phase 1
  2. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1
  3. ARC-02phase 1
  4. HBM7020phase 1
  5. SEP-380135phase 1

and 7 more — sign in to see them all

48%

Jiangsu HengRui Medicine: 52 of its 155 programs at phase 1

  1. Rifampinphase 1
  2. HRS-5817phase 1
  3. HRS-2189phase 1
  4. SHR-2017phase 1
  5. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1

and 47 more — sign in to see them all

34%
Phase 2

Otsuka: 2 of its 25 programs at phase 2

  1. VIS954phase 2
  2. OPC 131461phase 2
8%

Jiangsu HengRui Medicine: 50 of its 155 programs at phase 2

  1. SHR-1139phase 2
  2. SHR-1826phase 2
  3. SHR-9839phase 2
  4. SHR-2173phase 2
  5. HRS-4508phase 2

and 45 more — sign in to see them all

32%
Phase 3

Otsuka: 10 of its 25 programs at phase 3

  1. sibeprenlimabphase 3
  2. ulotarontphase 3
  3. centanafadine hydrochloridephase 3
  4. futibatinibphase 3
  5. repinatrabitphase 3

and 5 more — sign in to see them all

40%

Jiangsu HengRui Medicine: 51 of its 155 programs at phase 3

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  4. ribupatidephase 3
  5. notiretatug rezetecanphase 3

and 46 more — sign in to see them all

33%
Approved, new studies

Otsuka: 1 of its 25 programs at approved, new studies

  1. Tolvaptanapproved, new study
4%

Jiangsu HengRui Medicine: 2 of its 155 programs at approved, new studies

  1. vunakizumabapproved, new study
  2. remimazolam tosylateapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Otsuka8 readouts · 3 phase 3·

Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. difamilastphase 3 · Dec 0 · NCT07173478
  2. futibatinibphase 3 · Dec 0 · NCT05727176
·

Otsuka, Feb ’27: 1 program whose next study reaches primary completion

  1. repinatrabitphase 3 · Feb 9 · NCT07713758

Otsuka, Mar ’27: 1 program whose next study reaches primary completion

  1. sibeprenlimabphase 3 · Mar 13 · NCT06928142
·

Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. centanafadine hydrochloridephase 3 · May 27 · NCT07759154
  2. zipalertinibphase 3 · May 27 · NCT05973773

Otsuka, Jun ’27: 1 program whose next study reaches primary completion

  1. zimberelimabphase 3 · Jun 0 · NCT04999761
·

Otsuka, Aug ’27: 1 program whose next study reaches primary completion

  1. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1 · Aug 25 · NCT07525960
··
Jiangsu HengRui Medicine75 readouts · 11 phase 3

Jiangsu HengRui Medicine, Nov ’26: 2 programs whose next study reaches primary completion

  1. HRS-1780phase 3 · Nov 0 · NCT07470983
  2. SHR-1681phase 2 · Nov 0 · NCT06737731

Jiangsu HengRui Medicine, Dec ’26: 32 programs whose next study reaches primary completion, 4 in phase 3

  1. adebrelimabphase 3 · Dec 0 · NCT05482568
  2. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1 · Dec 0 · NCT06443489
  3. BP102phase 3 · Dec 0 · NCT06915142
  4. drotokibartphase 3 · Dec 0 · NCT07688772
  5. HRS-1596phase 1 · Dec 0 · NCT07841860

and 27 more — sign in to see them all

Jiangsu HengRui Medicine, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. RSS0393phase 3 · Jan 0 · NCT07543224
  2. SHR 3201phase 1 · Jan 0 · NCT07889349
  3. SHR-4375phase 2 · Jan 0 · NCT07298772
  4. HRS-5817phase 1 · Jan 30 · NCT07238647

Jiangsu HengRui Medicine, Feb ’27: 8 programs whose next study reaches primary completion

  1. FH-006phase 3 · Feb 0 · NCT07136142
  2. HRS-5346phase 2 · Feb 0 · NCT07767513
  3. HRS-8080phase 3 · Feb 0 · NCT07876596
  4. KRAS G12D Inhibitor HRS-4642phase 3 · Feb 0 · NCT07906691
  5. RSS0343phase 2 · Feb 0 · NCT07940829

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Mar ’27: 8 programs whose next study reaches primary completion, 3 in phase 3

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3 · Mar 0 · NCT06929624
  2. HRS-1893phase 3 · Mar 0 · NCT07269717
  3. HRS-4139phase 1 · Mar 0 · NCT07802964
  4. HRS-4729phase 2 · Mar 0 · NCT07690826
  5. ivarmacitinibphase 3 · Mar 0 · NCT07251595

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Apr ’27: 6 programs whose next study reaches primary completion

  1. HRS-4029phase 2 · Apr 0 · NCT07739160
  2. HRS-5632phase 2 · Apr 0 · NCT07185776
  3. SHR-1703phase 3 · Apr 0 · NCT07701239
  4. SHR-2173phase 2 · Apr 0 · NCT07354932
  5. SHR-4602phase 2 · Apr 0 · NCT06704828

and 1 more — sign in to see them all

Jiangsu HengRui Medicine, May ’27: 1 program whose next study reaches primary completion

  1. SHR-4712phase 1 · May 0 · NCT06993116

Jiangsu HengRui Medicine, Jun ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-7249phase 2 · Jun 0 · NCT07308392
  2. HRS8179phase 3 · Jun 0 · NCT06732648
  3. SHR-1819phase 3 · Jun 0 · NCT07321951
  4. SHR-1918phase 3 · Jun 0 · NCT07308392
  5. SHR-9803phase 2 · Jun 0 · NCT06906731

Jiangsu HengRui Medicine, Jul ’27: 5 programs whose next study reaches primary completion

  1. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3 · Jul 0 · NCT07682272
  2. ruzinuradphase 3 · Jul 0 · NCT07362355
  3. aumolertinibphase 3 · Jul 30 · NCT05503888
  4. retlirafusp alfaphase 3 · Jul 30 · NCT05503888
  5. SHR-9539phase 1 · Jul 31 · NCT06484777
·

Jiangsu HengRui Medicine, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-4508phase 2 · Sep 0 · NCT07003321
  2. garetatug rezetecanphase 3 · Sep 20 · NCT06649292

Jiangsu HengRui Medicine, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-5965phase 3 · Oct 0 · NCT07014826
  2. SHR-2524phase 1 · Oct 0 · NCT07478302
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Otsuka

New programs 0

None

Reached a new phase 1

  • VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study stopped 1

  • SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084

Primary completion later 3

Jiangsu HengRui Medicine

New programs 11

Reached a new phase 4

  • SHR-3167phase 3 · Oct 28 · Diabetes Mellitus, Type 2
  • HRS-6209phase 3 · Oct 14 · Breast Neoplasms
  • HRS-7172phase 2 · Sep 2 · Lung Neoplasms
  • FH-006phase 3 · Aug 25 · Lung Neoplasms

Study stopped 0

None

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 15 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionOtsukaJiangsu HengRui Medicine
Carcinoma, Non-Small-Cell Lungboth · compare here

Otsuka in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. zipalertinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Otsuka in Breast Neoplasms: 1 program

  1. futibatinibphase 3

Their studies: Otsuka’s studies of Breast Neoplasms in search

Jiangsu HengRui Medicine in Breast Neoplasms: 9 programs

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. HRS-8080phase 3
  4. ruzaltatug rezetecanphase 3
  5. HRS-6209phase 3

and 4 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Breast Neoplasms in search

Dermatitis, Atopicboth · compare here

Otsuka in Dermatitis, Atopic: 1 program

  1. difamilastphase 3

Their studies: Otsuka’s studies of Dermatitis, Atopic in search

Jiangsu HengRui Medicine in Dermatitis, Atopic: 6 programs

  1. ivarmacitinibphase 3
  2. drotokibartphase 3
  3. SHR-1905phase 3
  4. RSS0393phase 3
  5. SHR-1819phase 3

and 1 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Dermatitis, Atopic in search

Heart Failureboth · compare here

Otsuka in Heart Failure: 2 programs

  1. OPC 131461phase 2
  2. Tolvaptanapproved, new study

Their studies: Otsuka’s studies of Heart Failure in search

Jiangsu HengRui Medicine in Heart Failure: 5 programs

  1. HRS-1893phase 3
  2. HRS-9057phase 2
  3. HRS-5765phase 1
  4. HRS-7156phase 1
  5. SHR-4658phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Heart Failure in search

Lung Neoplasmsboth · compare here

Otsuka in Lung Neoplasms: 1 program

  1. zipalertinibphase 3

Their studies: Otsuka’s studies of Lung Neoplasms in search

Jiangsu HengRui Medicine in Lung Neoplasms: 6 programs

  1. FH-006phase 3
  2. BP102phase 3
  3. SHR-9839phase 2
  4. HRS-4508phase 2
  5. HRS-7172phase 2

and 1 more — sign in to see them all

Their studies: Jiangsu HengRui Medicine’s studies of Lung Neoplasms in search

Neoplasm Metastasisboth · compare here

Otsuka in Neoplasm Metastasis: 2 programs

  1. futibatinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Neoplasm Metastasis in search

Jiangsu HengRui Medicine in Neoplasm Metastasis: 4 programs

  1. HRS-8080phase 3
  2. retlirafusp alfaphase 3
  3. dalpiciclib isethionatephase 3
  4. SHR-2017phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Neoplasm Metastasis in search

Glomerulonephritis, IGAboth · compare here

Otsuka in Glomerulonephritis, IGA: 1 program

  1. sibeprenlimabphase 3

Their studies: Otsuka’s studies of Glomerulonephritis, IGA in search

Jiangsu HengRui Medicine in Glomerulonephritis, IGA: 3 programs

  1. HRS-5965phase 3
  2. SHR-2173phase 2
  3. HR19042phase 2

Their studies: Jiangsu HengRui Medicine’s studies of Glomerulonephritis, IGA in search

Arthritis, Rheumatoidboth · compare here

Otsuka in Arthritis, Rheumatoid: 1 program

  1. HBM7020phase 1

Their studies: Otsuka’s studies of Arthritis, Rheumatoid in search

Jiangsu HengRui Medicine in Arthritis, Rheumatoid: 2 programs

  1. ivarmacitinibphase 3
  2. SHR-3045phase 2

Their studies: Jiangsu HengRui Medicine’s studies of Arthritis, Rheumatoid in search

Biliary Tract Neoplasmsboth · compare here

Otsuka in Biliary Tract Neoplasms: 2 programs

  1. futibatinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Biliary Tract Neoplasms in search

Jiangsu HengRui Medicine in Biliary Tract Neoplasms: 1 program

  1. garetatug rezetecanphase 3

Their studies: Jiangsu HengRui Medicine’s studies of Biliary Tract Neoplasms in search

Lymphoma, B-Cellboth · compare here

Otsuka in Lymphoma, B-Cell: 1 program

  1. ARC-02phase 1

Their studies: Otsuka’s studies of Lymphoma, B-Cell in search

Jiangsu HengRui Medicine in Lymphoma, B-Cell: 2 programs

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3
  2. SHR-3079phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Lymphoma, B-Cell in search

Parkinson Diseaseboth · compare here

Otsuka in Parkinson Disease: 1 program

  1. ulotarontphase 3

Their studies: Otsuka’s studies of Parkinson Disease in search

Jiangsu HengRui Medicine in Parkinson Disease: 2 programs

  1. HRG2010phase 2
  2. benserazide, levodopa drug combinationphase 1

Their studies: Jiangsu HengRui Medicine’s studies of Parkinson Disease in search

Uterine Cervical Neoplasmsboth · compare here

Otsuka in Uterine Cervical Neoplasms: 1 program

  1. zimberelimabphase 3

Their studies: Otsuka’s studies of Uterine Cervical Neoplasms in search

Jiangsu HengRui Medicine in Uterine Cervical Neoplasms: 2 programs

  1. notiretatug rezetecanphase 3
  2. BP102phase 3

Their studies: Jiangsu HengRui Medicine’s studies of Uterine Cervical Neoplasms in search

Show all 15

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetOtsukaJiangsu HengRui Medicine
EGFRzipalertinibruleaumolertinibrule
PDCD1zimberelimabruleSHR-3045
A target, or a pathogen for a vaccine, known for: Otsuka 7 of 25 · Jiangsu HengRui Medicine 67 of 155 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Jiangsu HengRui Medicine: 1).